NAV

5-(4-Morpholin-4-Yl-Phenylsulfanyl)-2,4-Quinazolinediamine

Identification

Generic Name
5-(4-Morpholin-4-Yl-Phenylsulfanyl)-2,4-Quinazolinediamine
DrugBank Accession Number
DB02001
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 353.441
Monoisotopic: 353.131030945
Chemical Formula
C18H19N5OS
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UDihydrofolate reductase, mitochondrialNot AvailableHumans
UDihydrofolate reductaseNot AvailableYeast
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxazinanes
Sub Class
Morpholines
Direct Parent
Phenylmorpholines
Alternative Parents
Quinazolinamines / Diarylthioethers / Thiophenol ethers / Dialkylarylamines / Aniline and substituted anilines / Aminopyrimidines and derivatives / Imidolactams / Heteroaromatic compounds / Sulfenyl compounds / Oxacyclic compounds
show 5 more
Substituents
Amine / Aminopyrimidine / Aniline or substituted anilines / Aromatic heteropolycyclic compound / Aryl thioether / Azacycle / Benzenoid / Dialkyl ether / Dialkylarylamine / Diarylthioether
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
CZLWCJRHDBTCGQ-UHFFFAOYSA-N
InChI
InChI=1S/C18H19N5OS/c19-17-16-14(21-18(20)22-17)2-1-3-15(16)25-13-6-4-12(5-7-13)23-8-10-24-11-9-23/h1-7H,8-11H2,(H4,19,20,21,22)
IUPAC Name
5-{[4-(morpholin-4-yl)phenyl]sulfanyl}quinazoline-2,4-diamine
SMILES
NC1=NC2=C(C(N)=N1)C(SC1=CC=C(C=C1)N1CCOCC1)=CC=C2

References

General References
Not Available
PubChem Compound
3534
PubChem Substance
46507893
ChemSpider
3414
BindingDB
18048
ChEMBL
CHEMBL328827
ZINC
ZINC000008642910
PDBe Ligand
TQ6
PDB Entries
1ia4

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0675 mg/mLALOGPS
logP3.21ALOGPS
logP3.12Chemaxon
logS-3.7ALOGPS
pKa (Strongest Acidic)16.67Chemaxon
pKa (Strongest Basic)6.59Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area90.29 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity104.65 m3·mol-1Chemaxon
Polarizability37.64 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9383
Caco-2 permeable-0.5151
P-glycoprotein substrateSubstrate0.5442
P-glycoprotein inhibitor INon-inhibitor0.8342
P-glycoprotein inhibitor IINon-inhibitor0.7504
Renal organic cation transporterNon-inhibitor0.5386
CYP450 2C9 substrateNon-substrate0.8655
CYP450 2D6 substrateNon-substrate0.7088
CYP450 3A4 substrateNon-substrate0.6657
CYP450 1A2 substrateInhibitor0.6611
CYP450 2C9 inhibitorNon-inhibitor0.5735
CYP450 2D6 inhibitorNon-inhibitor0.8679
CYP450 2C19 inhibitorInhibitor0.5533
CYP450 3A4 inhibitorInhibitor0.6169
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.665
Ames testNon AMES toxic0.5124
CarcinogenicityNon-carcinogens0.8932
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3875 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7462
hERG inhibition (predictor II)Inhibitor0.6797
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Dihydrofolate reductase, mitochondrial
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Nadp binding
Specific Function
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Required to prevent uracil accumulation in mtDNA. Binds its own mRNA and that of DHFR.
Gene Name
DHFRL1
Uniprot ID
Q86XF0
Uniprot Name
Dihydrofolate reductase, mitochondrial
Molecular Weight
21619.88 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Details2. Dihydrofolate reductase
Kind
Protein
Organism
Yeast
Pharmacological action
Unknown
General Function
Nadp binding
Specific Function
Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.
Gene Name
DFR1
Uniprot ID
P22906
Uniprot Name
Dihydrofolate reductase
Molecular Weight
22138.295 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52